Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Genoveffa Franchini

Showing results (161-170 of 165) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 165 results.
NPJ Vaccines|December 19, 2025
ALFQ adjuvanted HIV-1 envelope protein vaccination elicits durable functional antibody and cellular responses in nonhuman primatesShikha Shrivastava, Joshua M Carmen, Jiae Kim, et al.
Nature Communications|February 2, 2023
HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCCMassimiliano Bissa, Sohyoung Kim, Veronica Galli, et al.
Nature Medicine|May 23, 2018
HIV vaccine candidate activation of hypoxia and the inflammasome in CD14<sup>+</sup> monocytes is associated with a decreased risk of SIV<sub>mac251</sub> acquisitionMonica Vaccari, Slim Fourati, Shari N Gordon, et al.
Nature Medicine|May 31, 2016
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisitionMonica Vaccari, Shari N Gordon, Slim Fourati, et al.
Iscience|February 8, 2021
Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidatesIsabela Silva de Castro, Giacomo Gorini, Rosemarie Mason, et al.
Pageof 17

Showing results (161-170 of 165) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 165 results.
NPJ Vaccines|December 19, 2025
ALFQ adjuvanted HIV-1 envelope protein vaccination elicits durable functional antibody and cellular responses in nonhuman primatesShikha Shrivastava, Joshua M Carmen, Jiae Kim, et al.
Nature Communications|February 2, 2023
HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCCMassimiliano Bissa, Sohyoung Kim, Veronica Galli, et al.
Nature Medicine|May 23, 2018
HIV vaccine candidate activation of hypoxia and the inflammasome in CD14<sup>+</sup> monocytes is associated with a decreased risk of SIV<sub>mac251</sub> acquisitionMonica Vaccari, Slim Fourati, Shari N Gordon, et al.
Nature Medicine|May 31, 2016
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisitionMonica Vaccari, Shari N Gordon, Slim Fourati, et al.
Iscience|February 8, 2021
Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidatesIsabela Silva de Castro, Giacomo Gorini, Rosemarie Mason, et al.
Pageof 17